Boehringer Ingelheim International Gmbh

Myrexis, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Gunter Koch

Arndt Hausherr

Rainer Hamm

Heinz-Peter Schmitt

Kerstin Schlarb

Ulrich Scholz

Michael H O'Neill

Georg Zerban

Bjoern Weyell

Christian Filser

Mike H O'Neill

Wolfgang Dersch

Gary G Sweetapple

Bjoem Weyell

Randall M Walker

David E Martin

Björn Weyell

The invention relates to a process for preparing the compound of formula 1 a valuable intermediate product in the synthesis of the pharmaceutical active substance dabigatran etexilate.

Method for producing an intermediate product of dabigatran etexilate

The invention relates to a process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterized in that

Process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof

The invention relates to a process for preparing a salt of an optionally substituted 4-benzimidazol-2-ylmethylamino)-benzamidine, characterised in that

Process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides

The present invention relates to crystalline polymorphs of 3-O-(3',3&#x2032;-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine salt ('DSB&#x2022;2NMG)'), pharmaceutical compositions of the same and use of the same as an active pharmaceutical agent in the treatment of HIV related disorders.

[object Object]

A process for preparing an optionally substituted 4-benzimidazol-2-ylmethylamino)benzamidine, the process comprising:

1,2,4-oxadiazol-5-one-4-(benzimidazolylmethylamino)benzamidine compounds

Process for the preparation of 4-(benzimidazolymethylamino) benzamidines

Growing community of inventors

Schwabenheim, Germany

Gunter Koch